Glenn Crater
- Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adultsBy Rashmi Mehta, Kelly Hardes, Anthony Cahn, Amy Newlands, Alison Donald, Andrew Preece, Dennis Kelleher and Glenn CraterRashmi Mehta1Clinical Pharmacology Modelling Simulation, GlaxoSmithKline, Research Triangle Park, United StatesKelly Hardes2Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomAnthony Cahn3Respiratory Medicine Discovery and Development, GlaxoSmithKline, Stevenage, United KingdomAmy Newlands4Discovery Biometrics, GlaxoSmithKline, Uxbridge, United KingdomAlison Donald5Quantitative Sciences, R&D, GlaxoSmithKline, Uxbridge, United KingdomAndrew Preece2Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomDennis Kelleher6Respiratory Medicine Discovery and Development, GlaxoSmithKline, Research Triangle Park, United StatesGlenn Crater7Respiratory and Immuno-Inflammation Medicine Development Center, GlaxoSmithKline, Research Triangle Park, United States
- Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPDBy Marc Decramer, Francois Maltais, Gregory Feldman, Jean Brooks, Lisa Willits, Stephanie Harris and Glenn CraterMarc Decramer1Respiratory Division, University Hospital, University of Leuven, Leuven, BelgiumFrancois Maltais2Institut Universitaire de Cardiologie et de Pneumologie, Faculté de Médecine, Université Laval, Laval, CanadaGregory Feldman3Research, S. Carolina Pharmaceutical, Spartanburg, United StatesJean Brooks4Respiratory Medicines Development Centre, GlaxoSmithKline, Uxbridge, United KingdomLisa Willits5Respiratory Medicines Development Centre S&P, GlaxoSmithKline, Uxbridge, United KingdomStephanie Harris6Medicines Development Centre, GlaxoSmithKline, Rearch Triangle Park, United StatesGlenn Crater7Respiratory and Immuno-Inflammation Medicine Development Center, GlaxoSmithKline, Rearch Triangle Park, United States
- Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPDBy Rashmi Mehta, Amy Newlands, Dennis Kelleher, Andrew Preece, Anthony Cahn and Glenn CraterRashmi Mehta1Clinical Pharmacology Modelling Simulation, GlaxoSmithKline, Research Triangle Park, United StatesAmy Newlands2Discovery Biometrics, GlaxoSmithKline, Uxbridge, United KingdomDennis Kelleher3Respiratory Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park, United StatesAndrew Preece4Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomAnthony Cahn5Respiratory Medicine Discovery and Development, GlaxoSmithKline, Stevenage, United KingdomGlenn Crater6Respiratory and Immuno-Inflammation Medicine Development Center, GlaxoSmithKline, Research Triangle Park, United States
- Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD)By Dennis Kelleher, Andrew Preece, Rashmi Mehta, Alison Donald, Kelly Hardes, Anthony Cahn and Glenn CraterDennis Kelleher1Respiratory Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park, United StatesAndrew Preece2Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomRashmi Mehta3Clinical Pharmacology Modelling Simulation, GlaxoSmithKline, Research Triangle Park, United StatesAlison Donald4Quantitative Sciences, R&D, GlaxoSmithKline, Uxbridge, United KingdomKelly Hardes2Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomAnthony Cahn5Respiratory Medicine Discovery and Development, GlaxoSmithKline, Stevenage, United KingdomGlenn Crater6Respiratory and Immuno-Inflammation Medicine Development Center, GlaxoSmithKline, Research Triangle Park, United States
- Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: Two randomised clinical trialsBy Francois Maltais, Sally Singh, Alison Donald, Alison Church, Glenn Crater, Aik Goh and John RileyFrancois Maltais1Centre De Pneumologie, Institut Universitaire De Cardiologie Et De Pneumologie De Québec, Québec, CanadaSally Singh2Cardiac and Pulmonary Rehabilitation, Glenfield Hospital, Leicester, United KingdomAlison Donald3Medicines Development, GlaxoSmithKline, Research Triangle Park, NC, United StatesAlison Church3Medicines Development, GlaxoSmithKline, Research Triangle Park, NC, United StatesGlenn Crater4Medicines Development, GlaxoSmithKline, Mississauga, ON, CanadaAik Goh5Medicines Development, GlaxoSmithKline, Uxbridge, United KingdomJohn Riley5Medicines Development, GlaxoSmithKline, Uxbridge, United Kingdom
- Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPDBy Marc Decramer, Antonio Anzueto, Edward Kerwin, Nathalie Richard, Glenn Crater, Maggie Tabberer, Stephanie Harris and Alison ChurchMarc Decramer1Respiratory Division, University Hospital, Leuven, BelgiumAntonio Anzueto2Pulmonary Critical-Care Medicine, University of Texas Health, Houston, TX, United StatesEdward Kerwin3Clinical Research Institute of Southern Oregon, Allergy and Asthma Center of Southern Oregon, Medford, OR, United StatesNathalie Richard4GlaxoSmithKline, Respiratory, Research Triangle Park, NC, United StatesGlenn Crater4GlaxoSmithKline, Respiratory, Research Triangle Park, NC, United StatesMaggie Tabberer5GlaxoSmithKline, Stockley Park, Uxbridge, United KingdomStephanie Harris4GlaxoSmithKline, Respiratory, Research Triangle Park, NC, United StatesAlison Church4GlaxoSmithKline, Respiratory, Research Triangle Park, NC, United States
- Further evidence that FeNO directed therapy reduces asthma exacerbationsBy Jorgen Syk, James Donohue, Kjell Alving, Nancy Herje and Glenn CraterJorgen Syk1Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, SwedenJames Donohue2Pulmonary Diseases & Critical Care Medicine, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC,Kjell Alving3Technical Development, Aerocrine AB, Solna, SwedenNancy Herje4Clinical Development & Medical Affairs, Aerocrine, Inc., Morrisville, NC,Glenn Crater4Clinical Development & Medical Affairs, Aerocrine, Inc., Morrisville, NC,
- Repeatability of FeNO measurements with an airway inflammation monitor using the 6 second (6s) and the 10 second (10s) exhalation modes in children 6 to 10 years of age with asthmaBy Neal Jain, Chelsea Bradshaw, Nancy Herje and Glenn CraterNeal Jain1Department of Pediatrics, San Tan Allergy & Asthma, Gilbert, AZ,Chelsea Bradshaw2Biostatistics, Stat-Tech Services, Chapel Hill, NC,Nancy Herje3Clinical Development & Medical Affairs, Aerocrine, Inc., Morrisville, NC,Glenn Crater3Clinical Development & Medical Affairs, Aerocrine, Inc., Morrisville, NC,
- Economic evaluation of fractional exhaled nitric oxide (FENO) for the management of adult asthma in SpainBy Ulla Seppala, Lorenzo Sabatelli, Joaquín Sastre and Glenn CraterUlla Seppala1Medical Affairs, Aerocrine AB, Solna, SwedenLorenzo Sabatelli2GLOBMOD, GLOBMOD, Barcelona, SpainJoaquín Sastre3Fundacion Jimenez Diaz, Universidad Autónoma de Madrid, Madrid, SpainGlenn Crater4Global Clinical Development & Medical Affairs, Aerocrine Inc., Morrisville, United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.